Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2013-01-05
Adverse events
Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 15.0); relationship: PROBABLE
Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-26 (study day 22.0); relationship: PROBABLE
Moderate APPLICATION SITE IRRITATION — outcome: RECOVERED/RESOLVED; onset 2013-01-26 (study day 22.0); relationship: PROBABLE
Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 15.0); relationship: PROBABLE
Moderate APPLICATION SITE PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-01-26 (study day 22.0); relationship: PROBABLE
Data queries
No data queries.